For decades, commercial real estate has been defined by four core asset classes. That structure is evolving. Life sciences real estate is emerging as a category of its own, driven by specialized infrastructure, long-term tenancy, and capital-intensive users. What was once considered niche is now drawing institutional investment and developer focus at a scale comparable to the industry’s most established sectors. That momentum accelerated in March 2026, when Governor Mike Braun announced a $1 billion performance-based investment in Indiana’s life sciences sector, targeting 100,000 high-wage jobs over the next decade and positioning Indiana as the re-shoring and expansion epicenter for human therapeutics, animal health, agritech, and biotech. For the commercial real estate sector, this level of public-private alignment signals a sustained pipeline of demand that will extend well beyond traditional asset boundaries. This article outlines what that shift looks like on the ground, from asset-level changes to emerging submarkets, and what investors and tenants should consider as the landscape continues to accelerate.

Indiana’s Life Sciences Sector: A Mature Market, Not an Emerging One 

Indiana’s $1 billion investment does not represent the start of the life sciences sector. It reinforces an already mature market entering a new phase of growth. In 2024, Indiana surpassed California to become the #1 life sciences exporter in the United States, generating $99 billion in economic activity. That output reflects a globally competitive production and commercialization base, supported by over 3,300 companies, 70,000 employees, and a $102 billion annual impact on the state’s economy. Globally recognized institutions anchor Indiana’s ecosystem. The state is home to the global headquarters of Eli Lilly and Company, the North American headquarters of Roche Diagnostics, and the top-ranked Indiana University School of Medicine. Capital investment reflects continued confidence: Eli Lilly and Company is advancing a $9 billion active pharmaceutical ingredient facility and a $4.5 billion Lilly Medicine Foundry in Lebanon, while Roche Diagnostics is advancing a $550 million diagnostics facility in Indianapolis. Novartis, Elanco Animal Health, Corteva Agriscience, and Cook Medical further strengthen the state’s position across therapeutics, animal health, and agriscience. At the metro level, the Indianapolis–Carmel–Greenwood metropolitan area ranks fourth in the United States for pharmaceutical employment, with 16,346 workers in the sector. More than 100 FDA approvals and 926 new patents were recorded in 2024 alone. Indiana is not cultivating a new life sciences market. It is scaling a mature ecosystem with the talent, infrastructure, and innovation pipeline to sustain long-term commercial real estate demand across lab, manufacturing, and hybrid asset types.

How Life Sciences Demand Is Reshaping Commercial Real Estate

Real estate follows industry. In Indiana, the demand for life sciences is already reshaping how space is designed, leased, and valued through several key forces: 

Demand Outpaces Supply: 

Life sciences companies require highly specialized space that most existing buildings cannot provide. This supply-demand imbalance allows landlords to command premium rents and positions developers to capture outsized returns through new construction and strategic conversions. 

Specialized Infrastructure Increases Tenant Stickiness: 

Lab environments often require capital investments of $200-$400 per square foot. Because buildouts are difficult to replicate, tenants commit to longer leases and are far less likely to relocate, resulting in stable, long-term occupancy. 

Capital-Backed Tenants Improve Income Durability: 

Life sciences occupiers are typically funded by venture capital, government grants, or large pharmaceutical companies, thereby reducing default risk and creating more predictable income streams than traditional office tenants. 

Cluster-Driven Demand Drives Location-Specific Value: 

Life sciences companies prioritize proximity to universities, hospitals, and research institutions, concentrating demand in specific submarkets and driving long-term property value appreciation. 

Hybrid Space Needs Redefining Asset Strategy: 

Life sciences users require a mix of office, R&D, and light manufacturing space within a single environment. Developers who deliver this integrated product are capturing premium tenants while traditional single-use assets face growing obsolescence. 

Expansion Creates Multiplier Effects: 

Major corporate investments generate downstream demand from suppliers, research partners, and logistics firms, amplifying absorption across office, industrial, and flex assets beyond core lab space.

Understanding the Unique Demands of Life Sciences Facilities 

Life sciences real estate operates under fundamentally different design, engineering, and regulatory requirements compared to traditional office space, directly impacting development costs, leasing strategy, and long-term asset performance. 

Lab Infrastructure: 

Wet labs require integrated sinks, gas lines, and chemical storage, which are not found in standard office layouts. These life sciences facilities also include specialized environments such as clean rooms, cold storage, and dedicated equipment zones, with flexible layouts that must adapt to evolving research workflows. 

Mechanical, Electrical, and Plumbing Systems: 

Life sciences buildings demand significantly more robust MEP infrastructure. Power requirements are higher, advanced HVAC systems are essential for air quality and contamination control, and many facilities incorporate redundant systems to ensure continuous operation. 

Safety and Regulatory Compliance: 

Buildings must meet strict biosafety and hazardous-material-handling standards, including designated Biosafety Levels. Proper waste management, chemical storage, and emergency infrastructure, such as eyewash stations and fume hoods, are mandatory requirements. 

Structural Design Requirements: 

Floor loads are typically higher to accommodate heavy lab equipment; ceiling heights are increased to accommodate extensive ductwork; and vibration control is necessary to protect sensitive research instruments and ensure precision across research activities. 

Building Systems and Operational Resilience: 

Life sciences facilities are equipped with backup generators and uninterrupted power supply systems. Purified water systems, specialized drainage, and tight environmental controls for temperature and humidity are standard requirements. 

Zoning and Location Considerations: 

Life sciences facilities face stricter zoning constraints than traditional office buildings due to the handling of chemical and biological materials. Location strategy prioritizes proximity to research institutions, hospitals, and established talent pipelines, concentrating demand in specific submarkets. 

Submarkets to Watch in 2026 and Beyond 

Indiana’s life sciences boom has concentrated focus on several key submarkets. Fishers is emerging as a strong fit for mid-size life sciences companies, supported by I-69 corridor access and a growing base of purpose-built and repositioned facilities. Downtown Indianapolis and the 16 Tech Innovation District are becoming important centers for early-stage biotech and health-tech occupiers seeking proximity to research and hospital infrastructure. Boone County and Lebanon are being reshaped by Lilly’s major manufacturing investment and the broader LEAP District buildout. Together, these locations reflect how the demand for life sciences is spreading across a connected regional cluster rather than concentrating in a single commercial real estate corridor.

The Strategic Role of Life Sciences Real Estate Brokers

As Indiana’s life sciences real estate grows more complex and competitive, the broker’s role has shifted from transactional support to strategic execution. Navigating this specialized asset class requires expertise beyond traditional leasing. 

Site Selection in a Supply-Constrained Market: 

Life sciences demand is concentrated around wet- and dry-lab capabilities, advanced utilities, and proximity to Indiana University and Purdue University. High-demand submarkets, including Carmel, Fishers, and Downtown Indianapolis, are seeing increased activity. A knowledgeable broker identifies viable sites based on infrastructure readiness, zoning, and long-term scalability. 

Structuring Complex Life Sciences Leases: 

Life sciences leases differ materially from traditional office agreements, often involving significant tenant improvements, specialized equipment provisions, and long-term operational considerations. Tenant representation ensures these complexities are addressed while protecting against unfavorable terms. 

Integrating Office, Lab, and Industrial Requirements: 

Most life sciences users require a hybrid environment combining administrative office space, R&D laboratories, and light manufacturing capabilities. Brokers with cross-asset expertise can align these requirements into a cohesive real estate strategy, reducing friction and improving execution. 

Navigating Incentives and Public Funding: 

Programs led by the Indiana Economic Development Corporation, including READI, offer grants, infrastructure support, and economic incentives. Brokers play a key role in identifying and securing these opportunities on behalf of clients. 

Managing Timing and Speed to Market: 

In life sciences, timing is closely tied to funding cycles and product development milestones. Delays in securing space can directly impact research timelines and commercialization. A proactive broker keeps projects on schedule. 

Ensuring Competitive Representation in a Tightening Market: 

As Indiana’s life sciences sector expands, competition for quality Indianapolis commercial real estate is intensifying. Dedicated tenant representation ensures companies are not negotiating in isolation against experienced landlords and developers. 

Conclusion

Indiana’s life sciences sector is no longer an emerging opportunity. It is a mature, expanding ecosystem where timing, asset positioning, and execution will determine who captures value. For investors and developers, the window to act is open but narrowing. Assets with the structural capacity to support lab, R&D, or hybrid use should be evaluated now, while the supply-demand imbalance continues to favor well-positioned properties. For tenants and business owners, waiting until space becomes a constraint results in reduced leverage and fewer options. Growth indicators such as new funding, hiring projections, or operational expansion should prompt earlier real estate planning. Incentives, site selection, lease structuring, and build-to-suit feasibility are interconnected decisions that require a strategic and informed approach. At Allies Commercial Realty, we bring cross-asset expertise across office, industrial, and flex properties, providing a single point of contact for life sciences real estate transactions in Indiana. Our team combines real-time market insight with deep knowledge of Indiana’s submarkets, available inventory, and deal structures. As the market continues to accelerate, the advantage will go to those who move early, act decisively, and execute with the right guidance.